Vasculogenic mimicry is a prognostic factor for postoperative survival in patients with glioblastoma

• Published in: Journal of neuro-oncology 2013-05, Vol.112 (3), p.339-345
• Main Authors: Wang, Shi-yong, Ke, Yi-quan, Lu, Guo-hui, Song, Zhen-hua, Yu, Li, Xiao, Sha, Sun, Xin-lin, Jiang, Xiao-dan, Yang, Zhi-lin, Hu, Chang-chen
• Format: Article
• Language: English
• Subjects: Adolescent; Adult; Aged; Antigens, CD34 - analysis; Antigens, CD34 - biosynthesis; Brain Neoplasms - blood supply; Brain Neoplasms - mortality; Brain Neoplasms - pathology; Female; Glioblastoma - blood supply; Glioblastoma - mortality; Glioblastoma - pathology; Humans; Kaplan-Meier Estimate; Laboratory Investigation; Male; Medicine; Medicine & Public Health; Middle Aged; Neurology; Oncology; Prognosis; Proportional Hazards Models; Young Adult
• ISSN: 0167-594X; 1573-7373
• DOI: 10.1007/s11060-013-1077-7

A previous report has confirmed the existence and clinical significance of vasculogenic mimicry (VM) in glioma. However, its conclusions about the negative clinical significance of VM in glioblastoma are based on a small group of patients and, thus, might be unconvincing. The aim of the present study was to reevaluate the clinical significance of VM in glioblastoma. Patients were classified as VM-positive or VM-negative according to CD34 and periodic acid-Schiff staining. The association between VM and the clinical characteristics of the patients was analyzed. Univariate and multivariate analyses were carried out to identify the independent prognostic factors for overall survival using the Cox regression hazard model. Survival times were estimated using the Kaplan–Meier method and compared using the log-rank test. Of all 86 glioblastomas, 23 were found to have VM. The presence of VM in glioblastoma was not associated with gender, age, Karnofsky performance status, hydrocephalus, tumor burden, microvessel density, tumor relapse, or the extent of tumor resection. The univariate and multivariate analyses revealed that VM is an independent prognostic factor for overall survival. The median survival time for patients with VM was 11.17 months compared with 16.10 months for those without VM ( P  = 0.017). In addition to VM, an age of 65 years or older, a KPS of 60 or less, a large tumor burden are significant prognostic factors for patient survival. Our data suggest that VM might be an independent adverse prognostic factor in newly diagnosed GBM, further prospective studies are needed to answer this question.